UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000051561
Receipt number R000058827
Scientific Title Changes in subfoveal choroidal thickness after intravitreal Aflibercept for diabetic macular edema.
Date of disclosure of the study information 2024/01/01
Last modified on 2023/07/09 16:51:46

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A clinical trial to study the effects of Aflibercept in patients with type 2 diabetes mellitus with reduced vision.

Acronym

DM

Scientific Title

Changes in subfoveal choroidal thickness after intravitreal Aflibercept for diabetic macular edema.

Scientific Title:Acronym

DME

Region

Asia(except Japan)


Condition

Condition

Diabetic Macular Edema

Classification by specialty

Endocrinology and Metabolism Ophthalmology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Changes in subfoveal thickness after intervention at 3, 6, and 9 months after 3rd injection.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Others

Developmental phase

Phase IV


Assessment

Primary outcomes

Reduction in subfoveal thickness after intravitreal Aflibercept

Key secondary outcomes

Improvement in vision after intervention


Base

Study type

Interventional


Study design

Basic design

n-of-1

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

No treatment

Stratification

NO

Dynamic allocation

YES

Institution consideration

Institution is considered as a block.

Blocking

YES

Concealment

No need to know


Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Intravitreal injection of Aflibercept

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

45 years-old <=

Age-upper limit

80 years-old >=

Gender

Male and Female

Key inclusion criteria

250u

Key exclusion criteria

Patients with proliferative diabetic retinopathy, prior intravitreal injections of anti-VEGFs or laser photocoagulation, pars plana vitrectomy, age-related macular degeneration, venous occlusion, ocular trauma, pregnancy, and ocular surgery (except cataract surgery) were excluded. Patients with less than 6 months follow-up after the 3rd injection were excluded.

Target sample size

100


Research contact person

Name of lead principal investigator

1st name Rahul
Middle name
Last name Bhargava

Organization

GS Medical College

Division name

Pilkhuwa

Zip code

245304

Address

NH9, Pilkhuwa, UP, India

TEL

+911204259971

Email

dean@gsmedicalcollege.in


Public contact

Name of contact person

1st name Prachi
Middle name
Last name Kumar

Organization

Yashoda

Division name

Ghaziabad

Zip code

201012

Address

Near Metro station Kaushambi

TEL

+911204181900

Homepage URL


Email

kumarprachi@yahoo.co.in


Sponsor or person

Institute

MMU Mullana Ambala

Institute

Department

Personal name



Funding Source

Organization

Self

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

MMU Mullana

Address

Ambala

Tel

+911731274476

Email

pstoregistrar@mmumullana.org


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2024 Year 01 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2022 Year 12 Month 20 Day

Date of IRB

2022 Year 12 Month 10 Day

Anticipated trial start date

2023 Year 09 Month 01 Day

Last follow-up date

2024 Year 05 Month 01 Day

Date of closure to data entry

2024 Year 06 Month 01 Day

Date trial data considered complete

2024 Year 06 Month 10 Day

Date analysis concluded

2024 Year 06 Month 25 Day


Other

Other related information



Management information

Registered date

2023 Year 07 Month 09 Day

Last modified on

2023 Year 07 Month 09 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000058827


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name